Literature DB >> 2109539

Addition of lithium carbonate to carbamazepine: hematological and thyroid effects.

K G Kramlinger1, R M Post.   

Abstract

In view of the increasing use of lithium-carbamazepine combination therapy for refractory psychiatric disorders, the authors assessed the clinical laboratory effects of adding lithium to carbamazepine in 23 patients with affective disorders. Lithium produced a robust reversal of carbamazepine-induced leukopenia, increasing WBCs, predominantly neutrophils, to levels significantly above placebo baseline values. The combination produced additive antithyroidal effects, resulting in greater decreases in T4 and free T4 than with carbamazepine alone; the addition of lithium was associated with the emergence of a modestly higher TSH level. The authors discuss clinical and theoretical implications of these findings.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2109539     DOI: 10.1176/ajp.147.5.615

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  10 in total

Review 1.  Mechanisms of clozapine-induced agranulocytosis.

Authors:  S L Gerson; H Meltzer
Journal:  Drug Saf       Date:  1992       Impact factor: 5.606

2.  Risperidone- and aripiprazole-induced leukopenia: a case report.

Authors:  Salah Uddin Qureshi; Eleonora Rubin
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008

Review 3.  Restarting clozapine after neutropenia: evaluating the possibilities and practicalities.

Authors:  Eromona Whiskey; David Taylor
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 4.  Thirty years of clinical experience with carbamazepine in the treatment of bipolar illness: principles and practice.

Authors:  Robert M Post; Terence A Ketter; Thomas Uhde; James C Ballenger
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

5.  Lithium dosage and leukocyte counts in psychiatric patients.

Authors:  L K Oyewumi; M McKnight; Z Z Cernovsky
Journal:  J Psychiatry Neurosci       Date:  1999-05       Impact factor: 6.186

Review 6.  Review of clinically important drug interactions with lithium.

Authors:  N S Harvey; S Merriman
Journal:  Drug Saf       Date:  1994-06       Impact factor: 5.606

7.  Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons.

Authors:  E Chalecka-Franaszek; D M Chuang
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-20       Impact factor: 11.205

Review 8.  Effects of lithium on inflammation.

Authors:  Ahmad Nassar; Abed N Azab
Journal:  ACS Chem Neurosci       Date:  2014-05-06       Impact factor: 4.418

Review 9.  Drug Interactions with Lithium: An Update.

Authors:  Patrick R Finley
Journal:  Clin Pharmacokinet       Date:  2016-08       Impact factor: 6.447

Review 10.  The New News about Lithium: An Underutilized Treatment in the United States.

Authors:  Robert M Post
Journal:  Neuropsychopharmacology       Date:  2017-10-04       Impact factor: 7.853

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.